Amgen Reports Third Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Wall Street ends down as US-Iran peace optimism fades
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Amgen (AMGN) PT Lowered to $250 at Jefferies
November 3, 2021 8:03 AM EDTJefferies analyst Michael Yee lowered the price target on Amgen (NASDAQ: AMGN) to $250.00 (from $270.00) while maintaining a Buy rating.
The analyst commented, "here were, and still are, worries about AMGN numbers, given no big guidance raises all year, and co says ongoing... More
Amgen (AMGN) Tops Q3 EPS by 41c, FY Guidance Tops Consensus
November 2, 2021 4:04 PM EDTAmgen (NASDAQ: AMGN) reported Q3 EPS of $4.67, $0.41 better than the analyst estimate of $4.26. Revenue for the quarter came in at $6.71 billion versus the consensus estimate of $6.69 billion.
GUIDANCE:
Amgen sees FY2021 EPS of $16.50-$17.10, versus the consensus of $16.43. Amgen sees... More
